Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKTX NASDAQ:GRTS NASDAQ:JSPR NASDAQ:MYNZ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTXAkari Therapeutics$10.25+0.1%$9.98$3.02▼$49.60$11.69M1.33404,867 shs39,113 shsGRTSGritstone bio$0.03$0.35$0.03▼$3.17$3.50M0.497.01 million shsN/AJSPRJasper Therapeutics$0.45+8.0%$0.72$0.32▼$7.19$12.73M3572,765 shs341,917 shsMYNZMainz Biomed$1.57-1.9%$1.72$0.55▼$4.43$14.22M0.31371,589 shs1.71 million shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTXAkari Therapeutics+5.68%-13.15%-37.67%+120.22%-78.12%GRTSGritstone bio0.00%0.00%0.00%0.00%0.00%JSPRJasper Therapeutics+0.29%-13.91%-49.22%-47.38%-92.41%MYNZMainz Biomed-1.84%+3.90%-37.50%+237.70%+13.48%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTXAkari Therapeutics$10.25+0.1%$9.98$3.02▼$49.60$11.69M1.33404,867 shs39,113 shsGRTSGritstone bio$0.03$0.35$0.03▼$3.17$3.50M0.497.01 million shsN/AJSPRJasper Therapeutics$0.45+8.0%$0.72$0.32▼$7.19$12.73M3572,765 shs341,917 shsMYNZMainz Biomed$1.57-1.9%$1.72$0.55▼$4.43$14.22M0.31371,589 shs1.71 million shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTXAkari Therapeutics+5.68%-13.15%-37.67%+120.22%-78.12%GRTSGritstone bio0.00%0.00%0.00%0.00%0.00%JSPRJasper Therapeutics+0.29%-13.91%-49.22%-47.38%-92.41%MYNZMainz Biomed-1.84%+3.90%-37.50%+237.70%+13.48%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKTXAkari Therapeutics 2.25Hold$89.00768.29% UpsideGRTSGritstone bio 0.00N/AN/AN/AJSPRJasper Therapeutics 2.33Hold$13.142,791.72% UpsideMYNZMainz Biomed 1.50ReduceN/AN/ACurrent Analyst Ratings BreakdownLatest GRTS, JSPR, MYNZ, and AKTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026JSPRJasper Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetSector Perform$4.00 ➝ $3.005/15/2026JSPRJasper Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold4/21/2026JSPRJasper Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026AKTXAkari Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/8/2026AKTXAkari Therapeutics Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold4/1/2026AKTXAkari Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$27.00(Data available from 7/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKTXAkari TherapeuticsN/AN/AN/AN/A$24.75 per shareN/AGRTSGritstone bio$496K7.05N/AN/A$0.54 per share0.06JSPRJasper TherapeuticsN/AN/AN/AN/A$0.15 per shareN/AMYNZMainz Biomed$659.94K21.55N/AN/A$2.61 per share0.60Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKTXAkari Therapeutics-$17.30MN/AN/AN/AN/AN/A-123.29%-63.01%8/18/2026 (Estimated)GRTSGritstone bio-$138.49M-$1.24N/AN/AN/A-910.50%-328.51%-82.53%N/AJSPRJasper Therapeutics-$75.80M-$3.23N/AN/AN/AN/A-613.51%-162.52%8/12/2026 (Estimated)MYNZMainz Biomed-$21.65M-$65.60N/AN/AN/AN/AN/AN/AN/ALatest GRTS, JSPR, MYNZ, and AKTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q1 2026AKTXAkari Therapeutics-$1.33-$688.00-$686.67N/AN/AN/A5/14/2026Q1 2026JSPRJasper Therapeutics-$0.46-$0.38+$0.08-$0.04N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAKTXAkari TherapeuticsN/AN/AN/AN/AN/AGRTSGritstone bioN/AN/AN/AN/AN/AJSPRJasper TherapeuticsN/AN/AN/AN/AN/AMYNZMainz BiomedN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKTXAkari TherapeuticsN/A0.270.27GRTSGritstone bio1.832.542.54JSPRJasper TherapeuticsN/A2.262.26MYNZMainz Biomed0.440.520.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKTXAkari Therapeutics5.06%GRTSGritstone bio48.46%JSPRJasper Therapeutics79.85%MYNZMainz BiomedN/AInsider OwnershipCompanyInsider OwnershipAKTXAkari Therapeutics32.20%GRTSGritstone bio4.61%JSPRJasper Therapeutics2.30%MYNZMainz Biomed18.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKTXAkari Therapeutics91.14 million776,000Not OptionableGRTSGritstone bio190108.57 million111.84 millionNo DataJSPRJasper Therapeutics2028.00 million27.35 millionOptionableMYNZMainz Biomed309.06 million7.41 millionNot OptionableGRTS, JSPR, MYNZ, and AKTX HeadlinesRecent News About These CompaniesMainz BioMed NV: Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors / Name change to Quantum Cyber (QUCY)March 12, 2026 | finanznachrichten.deStrategische Neuausrichtung: Mainz Biomed firmiert in Quantum Cyber um und ernennt neuen ChairmanMarch 11, 2026 | de.investing.comMainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of DirectorsMarch 11, 2026 | globenewswire.comMainz Biomed to Present at the Pancreatic Cancer Session at Digestive Disease Week, Demonstrating Effectiveness of mRNA Biomarkers in Blood SamplesFebruary 24, 2026 | markets.businessinsider.comMainz Biomed sichert sich 6 Millionen US-Dollar und richtet Fokus auf BauchspeicheldrüsenkrebsFebruary 17, 2026 | de.investing.comMainz Biomed secures $6 million private placement, shifts focus to US pancreatic cancer programFebruary 17, 2026 | msn.comMainz Biomed Announces 6.0 USD Million Private Placement and Strategic UpdateFebruary 17, 2026 | finance.yahoo.comMainz Biomed nimmt 2,15 Mio. US-Dollar über At-the-Market-Platzierung ein/nFebruary 10, 2026 | de.investing.comMainz Biomed Aktie: Neue Studiendaten vorausFebruary 7, 2026 | stock-world.deSMainz Biomed to Present Results of Pancreatic Cancer Verification Study at AACR 2026 Annual MeetingJanuary 14, 2026 | globenewswire.comMainz Biomed expects to complete eAArly DETECT 2 study in 2026January 6, 2026 | msn.comMainz Biomed Provides Review of 2025 HighlightsJanuary 5, 2026 | markets.businessinsider.comMainz Biomed Initiates eAArly DETECT 2 Clinical Study to Evaluate Next Generation Colorectal Cancer Test and Advances Pancreatic Cancer Screening ProgramJanuary 5, 2026 | quiverquant.comQMainz Biomed files $150M mixed securities shelfDecember 5, 2025 | msn.comMainz Biomed announces ColoAlert added to portfolio of DoctorBoxDecember 2, 2025 | msn.comDoctorBox Adds Mainz Biomed’s ColoAlert(R) to Its PortfolioDecember 2, 2025 | markets.businessinsider.comMainz BioMed NV: Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South AmericaNovember 18, 2025 | finanznachrichten.deMainz Biomed, OncoVanguard8 agree to bring ColoAlert to South AmericaNovember 18, 2025 | msn.comMainz Biomed Signs Memorandum of Understanding with OncoVanguard8 to Launch ColoAlert® Colorectal Cancer Screening in South AmericaNovember 18, 2025 | quiverquant.comQMainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South AmericaNovember 18, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGRTS, JSPR, MYNZ, and AKTX Company DescriptionsAkari Therapeutics NASDAQ:AKTX$10.25 +0.01 (+0.10%) Closing price 04:00 PM EasternExtended Trading$10.40 +0.15 (+1.47%) As of 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.Gritstone bio NASDAQ:GRTSGritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.Jasper Therapeutics NASDAQ:JSPR$0.45 +0.03 (+7.96%) Closing price 04:00 PM EasternExtended Trading$0.45 0.00 (-0.55%) As of 05:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.Mainz Biomed NASDAQ:MYNZ$1.57 -0.03 (-1.88%) As of 06/30/2026Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Uber’s Waymo Detour Tests the Stock’s Robotaxi Bull Case Copper Stocks Are Getting a Bigger Spotlight as Gold’s Rally Cracks AirJoule Unveils Prime System, Clearing Path to Commercialization Comcast’s NBCUniversal Split Puts Broadband Back in Focus Nike Q4 Beat Masks Core Weakness as Analysts Cut Price Targets Ouster Is Breaking Out as a Physical AI Leader: Here's What's Driving the Move Meta’s WhatsApp Shakeup Could Put India at the Center of Its Next Growth Push Hershey Stock May Be Near a Sweet Spot as Cocoa Pressure Eases Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
